Targets › IL10RB
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Dec 2029.
Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. (UniProt, Q08334)
Open in Phaseline: the race on IL10RB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Samer Gawrieh | Eflepedocokin Alfa (F-652) IL22 Receptor agonist | IL10RB, IL22RA1 | Phase 2 | Alcohol-associated Hepatitis | Dec 2029 |
Alcohol-associated Hepatitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.